Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported Results
Lecanemab demonstrated significantly lower risks of ARIA outcomes overall and in subgroups of interest compared to donanemab, including death related to ARIA or ICH, in ITC analysis. Future research understanding comparative safety profiles in real-world settings may inform treatment decisions.
Authors
- Ashley Holub (ORCID: https://orcid.org/0000-0003-0894-9184)
- Shumin Rui
- Keith A. Betts (ORCID: https://orcid.org/0000-0002-3088-7453)
- Anna Burke (ORCID: https://orcid.org/0000-0002-0775-2518)
- Sharon Cohen
- Christopher H van Dyck
- Marwan N. Sabbagh
Institutions
- Barrow Neurological Institute (US)
- Yale University (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70860_103048
- Primary Topic
- Intracerebral and Subarachnoid Hemorrhage Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00